Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $149.3 million.

  • 4D Molecular Therapeutics' Cash & Equivalents fell 74.11% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 74.11%. This contributed to the annual value of $149.3 million for FY2024, which is 40.05% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Cash & Equivalents of $149.3 million as of FY2024, which was down 40.05% from $249.1 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Cash & Equivalents ranged from a high of $276.7 million in FY2020 and a low of $52.4 million during FY2022.
  • Its 3-year average for Cash & Equivalents is $150.3 million, with a median of $149.3 million in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 457.33% in 2020, then plummeted by 65.78% in 2022.
  • 4D Molecular Therapeutics' Cash & Equivalents (Yearly) stood at $276.7 million in 2020, then slumped by 44.71% to $153.0 million in 2021, then tumbled by 65.78% to $52.4 million in 2022, then spiked by 375.84% to $249.1 million in 2023, then slumped by 40.05% to $149.3 million in 2024.